These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28659160)

  • 1. Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model.
    Jamshidfar S; Ardakani YH; Lavasani H; Rouini M
    Daru; 2017 Jun; 25(1):16. PubMed ID: 28659160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
    Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
    Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe.
    Nilchi S; Behdarvand D; Lavasani H; Rouini M; H Ardakani Y
    Drug Metab Pers Ther; 2018 Sep; 33(3):119-125. PubMed ID: 30070095
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
    Okubo M; Murayama N; Miura J; Chiba Y; Yamazaki H
    Biochem Pharmacol; 2015 Jan; 93(1):104-9. PubMed ID: 25475885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of MDMA Inhibitory Effect on CytochromeP450 3A4 in Isolated Perfused Rat Liver Model Using Tramadol.
    Sheikholeslami B; Tootoonchi Z; Lavasani H; Hosseinzadeh Ardakani Y; Rouini M
    Adv Pharm Bull; 2021 May; 11(3):530-536. PubMed ID: 34513628
    [No Abstract]   [Full Text] [Related]  

  • 7. Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation.
    Rodgers JT; Davydova NY; Paragas EM; Jones JP; Davydov DR
    Biochem Pharmacol; 2018 Oct; 156():86-98. PubMed ID: 30114388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential roles of phase I and phase II enzymes in 3,4-methylendioxymethamphetamine-induced cytotoxicity.
    Antolino-Lobo I; Meulenbelt J; Nijmeijer SM; Scherpenisse P; van den Berg M; van Duursen MB
    Drug Metab Dispos; 2010 Jul; 38(7):1105-12. PubMed ID: 20388857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour.
    Lind AB; Reis M; Bengtsson F; Jonzier-Perey M; Powell Golay K; Ahlner J; Baumann P; Dahl ML
    Clin Pharmacokinet; 2009; 48(1):63-70. PubMed ID: 19071885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
    Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
    Kasai M; Shioda K; Nisijima K; Yoshino T; Iwamura T; Kato S
    Neurosci Lett; 2011 Jul; 499(1):24-7. PubMed ID: 21621587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS.
    Borkar RM; Bhandi MM; Dubey AP; Ganga Reddy V; Komirishetty P; Nandekar PP; Sangamwar AT; Kamal A; Banerjee SK; Srinivas R
    Biomed Chromatogr; 2016 Oct; 30(10):1556-72. PubMed ID: 27006091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
    Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
    Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
    Steuer AE; Schmidhauser C; Tingelhoff EH; Schmid Y; Rickli A; Kraemer T; Liechti ME
    PLoS One; 2016; 11(3):e0150955. PubMed ID: 26967321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.
    O'Mathúna B; Farré M; Rostami-Hodjegan A; Yang J; Cuyàs E; Torrens M; Pardo R; Abanades S; Maluf S; Tucker GT; de la Torre R
    J Clin Psychopharmacol; 2008 Oct; 28(5):523-9. PubMed ID: 18794647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of mirtazapine by Cunninghamella elegans.
    Moody JD; Freeman JP; Fu PP; Cerniglia CE
    Drug Metab Dispos; 2002 Nov; 30(11):1274-9. PubMed ID: 12386135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).
    Pardo-Lozano R; Farré M; Yubero-Lahoz S; O'Mathúna B; Torrens M; Mustata C; Pérez-Mañá C; Langohr K; Cuyàs E; Carbó Ml; de la Torre R
    PLoS One; 2012; 7(10):e47599. PubMed ID: 23112822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in CYP1A2 activity in humans after 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) administration using caffeine as a probe drug.
    Yubero-Lahoz S; Pardo R; Farre M; Mathuna BÓ; Torrens M; Mustata C; Perez-Mañá C; Langohr K; Carbó ML; de la Torre R
    Drug Metab Pharmacokinet; 2012; 27(6):605-13. PubMed ID: 22673010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers.
    Kirchheiner J; Henckel HB; Meineke I; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2004 Dec; 24(6):647-52. PubMed ID: 15538128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers.
    Meyer MR; Peters FT; Maurer HH
    Drug Metab Dispos; 2008 Nov; 36(11):2345-54. PubMed ID: 18725511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.